Merck expands life science portfolio with $11.3 billion Bio-Techne deal.

{
  "signal_id": "f7d8ae7f-c896-4969-86d3-8efbb9d0e835",
  "signal_type": "news",
  "signal_subtype": "integrates_with",
  "detected_at": "2026-06-26T00:00:00+00:00",
  "company": {
    "name": "Bio-Techne",
    "domain": "bio-techne.com"
  },
  "data": {
    "url": "https://www.bionity.com/en/news/1189050/merck-expands-life-science-portfolio-with-11-3-billion-bio-techne-deal.html",
    "title": "Merck expands life science portfolio with $11.3 billion Bio-Techne deal.",
    "ticker": "NASDAQ:TECH",
    "excerpt": "Merck expands life science portfolio with $11.3 billion Bio-Techne deal.\n\nBio-Techne to bring portfolio with industry-leading multi-omics offering, analytical technologies and integrated workflow solutions across the scientific journey.\n\n26-Jun-2026\n\n\"This transaction is an important milestone towards delivering on our mid- to long-term strategic agenda. Bio-Techne is an outstanding fit that directly supports our strategic direction focused on delivering cutting-edge products and solutions across the entire industry value chain - from lab customers to those manufacturing in the biotech and pharmaceutical industries,\" said Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck.\n\nMerck and Bio-Techne Corporation, a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, entered into a definitive agreement pursuant to which Merck will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price.\n\nThe transaction would bring together two highly complementary and leading life sciences organizations, uniquely positioned to support customers across the full spectrum of life science workflows - from discovery and translational research...",
    "summary": "Bio-Techne integrated with Merck on Jun 26th '26.",
    "location": "Minneapolis, Minnesota, United States, Northern America, Americas",
    "planning": false,
    "image_url": "https://img.chemie.de/Portal/News/6a3e11934a293_pJsLxrn76.jpg?tr=w-7890,h-5917,cm-extract,x-0,y-0:n-xzoom",
    "confidence": 0.9562,
    "published_at": "2026-06-26T00:00:00Z",
    "location_data": [
      {
        "city": "Minneapolis",
        "state": "Minnesota",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-06-26",
    "article_sentence": "\"By combining Bio-Techne's scientific depth, innovation engine and differentiated portfolio with Merck's global scale, manufacturing excellence and customer reach, we are in a strong position to address some of the most important opportunities in life sciences and support our customers in accelerating the next generation of scientific discovery and therapeutic innovation.",
    "related_company_name": "Merck",
    "related_company_domain": "merck.com"
  }
}

curl https://signals.autobound.ai/v1/signals/f7d8ae7f-c896-4969-86d3-8efbb9d0e835 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bio-techne.com","limit":20}'